Daxor corporation acquires volumex® and megatope® from its existing supplier along with glofil® to enhance existing suite of diagnostics

Expected to improve margins and increase revenue streams oak ridge, tn, march 25, 2024 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for volumex and megatope from privately-held iso-tex diagnostics, inc. daxor has also acquired the exclusive rights to glofil, a drug that measures glomerular filtration rate (gfr), which iso-tex has been selling directly to its customer base. daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing.
DXR Ratings Summary
DXR Quant Ranking